2020
DOI: 10.1200/jco.2020.38.15_suppl.e23564
|View full text |Cite
|
Sign up to set email alerts
|

Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati).

Abstract: e23564 Background: Activity of temozolomide (TEM) and irinotecan (IRI) in recurrent Ewing sarcoma (EWS) was demonstrated. Few data are available on TEMIRI use upfront. Biological predictive factors are lacking. Methods: This multi-institutional retrospective study (NCT03542097) included 59 patients with EWS. 8 patients with very high risk (HR) EWS (multivisceral ± bone marrow) received TEMIRI (TEM 100 mg/m2/day oral, and IRI 40 mg/m2/day intravenous, days 1-5, every 21 days) upfront, 51 patients after relapse… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Palmerini E, et al [ 16 ] assessed efficacy of the IT regimen in 59 patients with advanced ES. Eight high-risk patients received the IT regimen upfront and 51 patients after relapse.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Palmerini E, et al [ 16 ] assessed efficacy of the IT regimen in 59 patients with advanced ES. Eight high-risk patients received the IT regimen upfront and 51 patients after relapse.…”
Section: Discussionmentioning
confidence: 99%
“…This expression did not significantly correlate with outcomes following the IT regimen. Further, survival times from the initiation of the primary chemotherapy regimen were not compared by MGMT status [ 16 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation